UroSurge Urinary Incontinence Device To Hit U.S. Market In Next 2 Weeks
This article was originally published in The Gray Sheet
Executive Summary
UroSurge says it will launch the Percutaneous Stoller Afferent Nerve Stimulation (SANS) system in the next two weeks for symptomatic treatment of urinary urgency, frequency or urge incontinence. FDA cleared the device Feb. 9 via a de novo 510(k) with clinical trials as a special control.
You may also be interested in...
Timm Medical Broadens Incontinence Portfolio With UroSurge Acquisition
Timm Medical Technologies plans to proceed with clinical trials of UroSurge's implantable SANS stoller afferent nerve stimulation device for treatment of urinary incontinence if its acquisition of UroSurge closes May 31 as planned. Financial terms of the deal were not disclosed.
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.